To study if obesity is a risk factor in elderly patients (>60 years) with aggressive B-cell lymphoma, the outcomes of 576 elderly patients treated with rituximab in the RICOVER-60 trial were analysed in a retrospective study with regard to body mass index (BMI) and gender. Of the 576 patients, 1% had low body weight (BMI < 18Á5), 38% were normal weight (18Á5 ≤ BMI < 25), 42% were overweight (25 ≤ BMI < 30) and 19% were obese (BMI ≥ 30). Event-free (EFS), progression-free (PFS) and overall survival (OS) according to BMI showed no significant differences for all and for male patients. EFS (P = 0Á041), PFS (P = 0Á038) and OS (P = 0Á031) were significantly better for female non-obese patients. A multivariate analysis adjusted for International Prognostic Index risk factors confirmed these results, with the following hazard ratios (HR) for obesity (BMI ≥ 30) for EFS/PFS/OS: all patients -1Á4/1Á4/1Á4 (not significant); male patients -1Á2/ 1Á2/1Á0 (not significant) and female patients -1Á7 (P = 0Á032)/1Á9 (P = 0Á022)/2Á0 (P = 0Á017). In conclusion, obesity is a risk factor that influences treatment outcome in elderly female patients with aggressive B-cell lymphoma treated with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone). The inferior outcomes in obese female patients may be due to faster rituximab clearance in obese females.
obese breast cancer patients (Ewertz et al, 2012; Copson et al, 2015) ; on the other hand, some studies observed no differences in outcome and survival for patients with colorectal and endometrial cancer (Crosbie et al, 2012; Parkin et al, 2014) . The data are sparse for haematological malignancies: obesity seems to be a risk factor in acute leukaemia patients and is associated with poorer outcome in one retrospective analysis (Bhaskaran et al, 2014; Crysandt et al, 2016) . For obese patients, a higher relative risk for developing diffuse large B-cell lymphoma (DLBCL) is described in one study (Castillo et al, 2014) . Data regarding outcome for patients with lymphoma are conflicting. Hong et al (2014) reported no association of BMI and outcome of patients with DLBCL, Hodgkin lymphoma (HL) and follicular lymphoma (FL) in a retrospective analysis of three different trials. To the contrary, Weiss et al (2014) found an increased survival for patients with higher BMI (BMI ≥ 25) compared to patients with BMI < 25 in a retrospective single centre study. A retrospective study of 2534 patients, including mostly Caucasian male veterans, also found an improved survival for obese patients with DLBCL (Carson et al, 2012) . On the other hand, a multi-ethnic study found low-normal weight (BMI ≤ 22Á5) and overweight (BMI ≥ 30) associated with a higher Non-Hodgkin lymphoma (NHL)-specific mortality (Leo et al, 2014) . The same results were found in an Asian population, showing a significantly shorter overall survival (OS) in underweight (BMI ≤ 18Á5) and obese (BMI ≥ 30) patients with DLBCL (Hwang et al, 2015) .
These studies consisted partly of inhomogeneous, in some studies all-male, patient populations. Gender differences, the impact of chemotherapy doses actually applied (as opposed to planned dose) or dose reductions, such as dose capping at 2 m 2 body surface area (BSA), have almost never been addressed or considered in published data to date. Sex and weight independently affect rituximab clearance in the elderly with a faster rituximab clearance in elderly male patients and in patients with higher weight . This sex-dependent effect and a higher weight in male patients results in a smaller improvement by the addition of rituximab to chemotherapy compared with females, as shown in the RICOVER-60 trial (Muller et al, 2012) . Dose capping is often used in obese patients although full dosage in the obese is not associated with higher toxicity, but may lead to decreased efficacy, and is therefore no longer recommended in obese patients (Griggs et al, 2012) . Lastly, the quantity of treatment actually delivered to the patient is one of the most important factors for outcome in DLBCL (Bosly et al, 2008) . Therefore, we analysed the outcome and treatment adherence of 576 well-defined patients with aggressive B-cell lymphomas treated with R-CHOP-14 (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone, at 14-day intervals) in the RICOVER-60 trial with regard to body mass index (BMI ≥ 30 vs. BMI < 30) and gender in order to evaluate if obesity is a risk factor in this patient population.
Material and methods

Patients and treatment
We analysed 576 elderly patients (61-80 years of age) with untreated aggressive CD20 + B-cell lymphoma (DLBCL, grade 3 FL, lymphoblastic lymphoma, blastoid mantle cell lymphoma and Burkitt lymphoma) included in the RICOVER-60 trial (Pfreundschuh et al, 2008) . The RICOVER-60 trial compared 6 or 8 cycles of CHOP-14 with or without eight applications of rituximab in 1222 elderly patients in a randomized fashion. Patients with bulky disease or extra-lymphatic involvement received consolidative involved field (IF) radiation with 36 Gy. Only patients included in this prospective trial who received rituximab and for whom BMI was available were included in the following analysis. Data validation was performed on an independent set of 151 patients included in the phase II RICOVER-noRTh trial , treated with six cycles of CHOP-14 plus eight applications of rituximab but without consolidation radiotherapy.
Measurements
Body mass index was calculated for each cycle of chemoimmunotherapy [provided weight was documented) as weight (in kg) divided by the square of height (in metres). BMI (kg/ m 2 )] was groupd according to the World Health Organisation (WHO) classification (WHO 1995) as: underweight (BMI < 18Á5), normal weight (18Á5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥ 30). No significant changes in body weight or BMI occurred during treatment cycles ( Figure S1A ), therefore BMI at Cycle 1 was used for the following analysis.
Statistical analysis
Event-free survival (EFS), as the primary endpoint of the RICOVER-60/RICOVER-noRTh trials, was defined as the time from randomisation/registration to disease progression, start of salvage treatment, additional (unplanned) treatments, relapse, or death from any cause. Progression-free survival (PFS) was defined as time from randomisation/registration to disease progression, relapse, or death from any cause. Overall survival (OS) was defined as the time from randomization/registration to death from any cause. EFS, PFS and OS were estimated according to Kaplan and Meier (1958) . Before the analysis, Kaplan-Meier plots were created for EFS, PFS and OS with respect to the four BMI groups according to the WHO classification (data not shown). Due to the clinical interest in analysing the outcome of obese patients and significantly worse (EFS, PFS, OS) outcome of obese patients in comparison to that of overweight patients, we used the BMI cut-off point of ≥30.
Given that data from the literature indicate that obesity and gender influence the pharmacokinetics of rituximab (Muller et al, 2012; Pfreundschuh et al, 2014) , and observing a relevant but non-significant interaction term for BMI [BMI ≥ 30 vs. BMI < 30) and gender (male vs. female) (HR: 0Á7, 95% CI [0Á4; 1Á5], P = 0Á369] we decided to analyse all patients, and also, male and female patients separately. Univariable outcome analyses were performed using a cutoff of BMI ≥ 30 and log-rank test results are presented. Proportional hazard models were adjusted for the factors of the International Prognostic Index (IPI, i.e. age >60 years, lactate dehydrogenase (LDH) > normal, Eastern Cooperative Oncology Group performance score (ECOG PS) > 1, stages III/IV, and extralymphatic involvement > 1) and additionally, in a further analysis, for gender, age > 70 years, 6 or 8 cycles of CHOP, radiotherapy (yes or no) and relative dose of cyclophosphamide: HRs with 95% CIs and P-values are presented. For comparison of patient characteristics, chi-square and, if necessary, Fisher's exact tests were used.
Within the RICOVER-60 protocol, dose reduction strategies were foreseen in case of toxicity and the reduction of the cytotoxic drugs cyclophosphamide and doxorubicin were to be performed in parallel, resulting in nearly the same relative doses for both substances. We decided to present here the dose curves for cyclophosphamide only. For the estimation of the relative dose of cyclophosphamide (representing the protocol adherence of CHOP therapy), the body surface area (BSA) was assessed according to Du Bois and Du Bois (1989) for each cycles. These values were used to assess the absolute dose of cyclophosphamide (mg) given per BSA (m 2 )
for each cycle for all patients. The relative dose of cyclophosphamide was then calculated as the sum of given dose (mg/ m 2 ) over the cycles divided by the planned dose for 6 (6 9 750 mg/m 2 )/8 (8 9 750 mg/m 2 ) cycles according to the RICOVER-60 protocol. Curves of relative dose were estimated according to Kaplan and Meier technique (Wunderlich et al, 2003) . The significance level was P = 0Á05 (two-sided). A preplanned subgroup analysis was done according to gender. Statistical analyses were done with IBM SPSS Statistics 22 software (SPSS, Chicago, IL).
Results
Clinical presentation
All patients were older than 60 years, 36% of patients were older than 70 years. Forty-six percent of the patients were female and 54% were male. The BMI results for male and female patients varied only slightly during the therapy cycles and the frequencies for various BMI subgroups before start of chemoimmunotherapy were comparable for males and females ( Figure S1A , B). Therefore, we used the BMI before any treatment for classification into obese and non-obese patients. Of the 610 rituximab-treated patients from the RICOVER-60 trial, 576 had documented weight and height information before start of treatment and were eligible for this analysis. Of these 576 patients, 1% were underweight (BMI < 18Á5), 38% were normal weight (18Á5 ≤ BMI < 25), 42% were overweight (25 ≤ BMI < 30) and 19% of patients were obese (BMI ≥ 30) at the start of treatment. The inclusion criteria of the RICOVER-60 and RICOVER-noRTh trial were identical and therefore patient characteristics were similar with a trend to higher age within RICOVER-noRTh trial (Table I) . Clinical characteristics regarding age, IPI risk factors and IPI were not significantly different between obese (BMI ≥ 30) and non-obese patients (BMI < 30) within the RICOVER-60 and RICOVER-noRTh trials, and within male and female patients in both trials (Table I) . Within the RICOVER-60 trial, a significantly lower proportion of obese had more than one extralymphatic site (11% vs. 20%, P = 0Á038), but this difference was not observed in the RICOVER-noRTh cohort.
Dosage, early termination of therapy and haemotoxicities
Relative doses of cyclophosphamide over all cycles showed a small difference between patients with BMI ≥ 30 or BMI < 30. Obese male patients received less cyclophosphamide than non-obese males; obese and non-obese females received nearly comparable relative cyclophosphamide doses (Fig 1) . Of the total study cohort (n = 576), 71% of patients (73% male, 70% female) completed their therapy as planned per protocol. Patients with BMI ≥ 30 completed treatment less frequently (61%) than the patients with BMI < 30 (74%), with a bigger difference in male (59% vs. 75%) than in female patients (62% vs. 72%) (Table II) . Obese female patients received an higher relative dose in relation to actually given cycles than females with BMI < 30 (data not shown), compensating for the earlier termination of chemoimmunotherapy in the obese female patients and resulting in similar dose curves (Fig 1) . Overall, obese and non-obese female received comparable doses, but obese male patients received lower doses than non-obese males.
The median duration of therapy was very similar between obese and non-obese male and female patients and comparable between the male and female group (data not shown).
There were no relevant differences between obese and non-obese patients regarding haemotoxicity or infections during cycles (Table II) .
Obesity and outcome
EFS, PFS and OS according to BMI (BMI ≥ 30 vs. BMI < 30) were not different for all patients and for male patients. For females, EFS (P = 0Á041), PFS (P = 0Á038) and OS (P = 0Á031) were significantly better for non-obese patients compared to those for obese patients (Fig 2A) . Multivariate analysis adjusting for IPI risk factors (LDH >nor-mal, ECOG PS >1, stage III/IV, extralymphatic involvement >1) confirmed these results with the following HRs for obesity (BMI ≥ 30) for EFS/PFS/OS: all patients -1Á4/1Á4/1Á4 (not significant); male patients -1Á2/1Á2/1Á0 (not significant); female patients -1Á7 (P = 0Á032)/1Á9 (P = 0Á022)/2Á0 (P = 0Á017) (Table III) . These results were consistent also after additional adjustment for gender, age > 70 years, 6 or 8 cycles of CHOP, radiotherapy (yes or no) and relative dose of cyclophosphamide (<3rd quartile vs. ≥3rd quartile of relative dose). These findings were confirmed in an independent analysis of 151 patients from the RICOVER-noRTh trial (Fig 2B) . The HRs for EFS/PFS/OS in the RICOVER-noRTh cohort are comparable to the HRs from the RICOVER-60 cohort: all patients -1Á4/1Á4/1Á7; male patients -0Á7/0Á9/1Á5; female patients -2Á6/2Á0/1Á8. Due to the small sample size only the HR for female patients for the EFS was significant (P = 0Á031) in the RICOVER-noRTh cohort (Table III) .
In addition, we analysed the impact of the fact that the dose of chemoimmunotherapy was capped for patients with BSA > 2 m 2 in some centres, as per institutional standards. The respective patients were dosed with a calculated dose for 2 m 2 or less. There was no difference in EFS, PFS and OS in male and female patients when cyclophosphamide dose was reduced due to a BSA > 2 m 2 or not (data not shown).
Discussion
To the best of our knowledge, this is the largest analysis of obesity as a risk factor in elderly patients with aggressive CD20 + B-cell lymphoma treated with R-CHOP. In contrast to previously published data, our analysis presents a welldefined study population including both male and female patients treated in a prospective randomised trial in the rituximab era. Treatment was standardised within a welldefined dose-dense protocol (R-CHOP-14) including identical supportive measures and dose reduction strategies for all patients. In addition, the exact amount of therapy delivered to each patient, which is highly important for the outcome in patients with aggressive NHL, has been documented for all patients in this study. Our results were confirmed in a second cohort (RICOVER-noRTh; Held et al, 2014) with a comparable patient population and nearly identical therapy. Nevertheless, there are some limitations to our study. Our trial patient population may have been subjected to more selection than that from a general population, however, we do not expect that this will influence the effect of obesity on EFS (i) male patients outcome. In addition, data were acquired using the R-CHOP-14 regimen, which has a different treatment intensity than R-CHOP-21 and which represents the standard treatment for elderly patients. Therefore further analyses regarding R-CHOP-21 and other regimens may be necessary; however, several trials have documented identical outcome for patients treated with R-CHOP-14 or R-CHOP-21 (Cunningham et al, 2013). The major finding in our study is that obesity is a risk factor for elderly female patients over 60 years of age with aggressive B-cell lymphoma treated with R-CHOP-14 with regard to EFS, PFS and OS, even after adjustment for IPI factors. These findings were also similar when adjusted for age >70 years, 6 or 8 cycles of CHOP, addition of radiotherapy and relative dose of cyclophosphamide, and were confirmed in an independent second cohort (RICOVER-noRTh).
One reason for the inferior outcome of obese female patients in this study might be a faster rituximab clearance in this subgroup. Pharmacokinetic studies revealed a better outcome in elderly females compared to elderly males and a slower and therefore more favourable rituximab clearance compared to all other risk groups (elderly males, young males and females). This effect is due to an age-dependent decrease of rituximab clearance limited to elderly females only and therefore a longer exposure time to the drug resulting in a greater benefit . On the other hand, rituximab clearance increases with body weight (Muller et al, 2012) , probably overturning the decrease in rituximab clearance in elderly obese women. This is supported by the fact that there was no gender effect in EFS, PFS or OS when patients treated without rituximab in the RICOVER-60 trial were studied. In that subgroup, only EFS for obese patients (BMI ≥ 30) was significantly better, irrespective of gender; PFS and OS showed no significant differences between groups. These results are consistent in multivariable Cox models adjusted for the IPI factors (Tables SI and SII; Figure S2 ). In our view, these data do not contradict the results published by Weiss et al (2014) and Carson et al (2012) who found a better outcome in the obese subset of patients. However, a significant difference between our analysis and the results of these studies is the high percentage of males in these two trials, possibly making it difficult to uncover the strong gender effect observed in our study. In addition, the analyses reported by Carson et al (2012) and Hong et al (2014) included patients who had and had not received rituximab; in contrast, our study included only patients receiving rituximab. However, Hong et al (2014) found a trend (P = 0Á09) for an interaction between gender and "induction therapy" (CHOP vs. R-CHOP) for patients with DLBCL, implying a finding consistent with ours. This observation clearly demonstrates that gender and the actual applied dose must be incorporated in such an analysis.
EFS (i) male patients
There is some evidence that a lower relative dose intensity of therapy might be associated with worse outcome in DLBCL (Lepage et al, 1993; Lyman, 2006 Lyman, , 2011 Bosly et al, 2008; Griggs et al, 2012) . Early termination of therapy due to toxicity was more frequent in the obese group (21% vs. 16%) and fewer patients completed all planned chemotherapy in this group (61% vs. 74%). This was seen for male and female patients with a bigger difference in male patients. However obese females received higher relative doses of cyclophosphamide than non-obese females, which may have compensated for the relative effect of early termination of therapy observed in the obese females, resulting in nearly identical doses for these two groups. However obese male patients received remarkably lower doses than non-obese males (Fig 1) . In our analysis "dose capping" at 2 m 2 BSA had no influence on EFS, PFS and OS in male or female patients.
In conclusion, BMI ≥ 30 is a risk factor in elderly female patients with aggressive CD20 + B-cell lymphoma treated with R-CHOP. A relevant lower dosage or dose intensity in obese female patients was not observed in comparison to nonobese females and is therefore not the reason for the inferior outcome in our analysis. The worse outcome for obese females might be the result of faster rituximab clearance in elderly female patients. In a younger population, these issues related to gender and obesity may not be evident. Therefore, an analysis of a group of younger patients included in different German High-Grade NHL Study Group (DSHNHL) trials is currently being conducted.
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